The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Despite enormous advances in terms of therapeutic strategies, multiple myeloma (MM) still remains an incurable disease with MM patients often becoming resistant to standard treatments. To date, multiple combined and targeted therapies have proven to be more beneficial compared to monotherapy approaches, leading to a decrease in drug resistance and an improvement in median overall survival in patients...
Introduction
Although daratumumab‐containing regimens improve multiple myeloma (MM) outcomes, recurrence is inevitable.
Methods and Objective
We performed a retrospective study using the Canadian Myeloma Research Group Database to benchmark the efficacy of carfilzomib‐ or pomalidomide‐based therapies immediately following progression on daratumumab treatment.
Results
We identified 178 such patients;...